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Referrals of cancer versus non-cancer patients to a palliative care consult 
team : do they differ ? 
Depuis la fin du XXème siècle, les soins palliatifs se sont développés essentiellement autour de patients 
souffrant de cancer en phase terminale. Or depuis une dizaine d'années, un nombre croissant d'études 
rapporte que les patients souffrant de maladies non cancéreuses avancées expérimentent également 
une variété de problèmes, de dimension physique, psychosociale ou spirituelle. Ces problèmes peuvent 
avoir un fort impact sur leur qualité de vie. Malheureusement, seule une ~inorité de patients non 
cancéreux en phase terminale a accès à des soins palliatifs. 
Le but de cette étude est de mieux comprendre les similitudes et les différences entre les patients 
cancéreux et non cancéreux lorsqu'ils sont encore hospitalisés dans un hôpital universitaire de soins 
aigus et réferrés à une équipe mobile de soins palliatifs intrahospitalière. 
Méthodologie : 
Dans cette étude rétrospective, les dossiers des 1 OO premiers patients non· cancéreux adres.sés à 
l'équipe mobile de soins palliatifs (EMSP) ont été comparés avec ceux de 506 patients cancéreux, 
durant la même période (2000-2001). 
Nous avons répertorié leurs profils démographiques, les types de demandes des professionnels de 1 ère 
ligne s'adressant à l'EMSP, les symptômes ainsi que la médication des patients. · 
Conclusions : 
Dans les deux groupes de patients, nous. avons retrouvé de manière égale un haut taux de 
symptômes: 79% de patients non cancéreux et 71% de patients cancéreux expérimentent au moins 3 
symptômes ou plus. Cependant, malgré cette similitude en termes d'inconfort, l'équipe de soins 
palliatifs est appelée plus tardivement pour les patients non cancéreux. Au vu des problèmes de 
communication verbale chez les patients non cancéreux, les demandes d'évaluation formulées auprès 
de l'EMSP sont plus orientées vers « une évaluation globale » au lieu d'une aide sur un problème 
spécifique. Nous retrouvons également une différence en termes d'analgésie entre les deux populations 
de patients, les patients non cancéreux sont plus fréquemment en surdosage. Selon nos données, un 
plus grand taux de décès survient à l'hôpital auprès des patients non cancéreux. 
Dans les limites de cette étude, les résultats permettent de confirmer que les patients non cancéreux 
hospitalisés dans un hôpital de soins aigus sont encore peu référés à une EMSP et très tardivement. 
Pour y rémédier, il serait nécessaire de contourner ces obstacles au vu des problèmes d'évaluation et 
d'identification exposés dans cette étude, d'améliorer la collaboration avec les professionnels de 1 ère 
ligne et peut-être de mettre en place des guidelines institutionnels afin que tous les patients palliatifs 
puissent avoir la meilleure qualité de vie possible, et ce, jusqu'au bout de leur trajectoire hospitalière. 
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Abstract /This retrospective study compared î OO con-
secutive non-cancer (NC) patients referred to a pallia-
tive care consult team (PCT) in a Swiss university hos-
pital to 506 cancer (C) patients referred during the 
same period. The frequencies of reported symptoms 
were similar in both groups. The main reasons for refer-
ral in the NC group were symptom contrai, global eval-
uation, and assistance with discharge. Requests for 
symptom control predominated in the C group. Prier to 
the first visit, 50% of Ne· patients were on opioids, 
compared to 58% of C patients. After the first visit, the 
proportion of NC patients on opioids increased to 64% 
and the proportion of C patients to 73%. The median 
daily oral morphine equivalent dose for NC patients 
taking opioids prier to the first PCT visit was higher 
than that for C patients (60 mg versus 45 mg). At the 
time of death or discharge, the percentage of NC 
patients on opioids was 64%, while that of C patients 
was 76%. Moreover, ~~C patients were on significantly 
lower median doses of opioids than C patients (3î mg 
versus 60 mg). Over half the NC patients died during 
hospitalization, as compared to 33% of C patients. 
Only 6% of NC patients were discharged to palliative 
care units, as compared to 22% of C patients. 
[Key words: Palli.ative care, non-cancer, cancer, consult 
service, consult team] 
Résumé / Dans une étude rétrospective nous avons 
comparé les dossiers de î OO patients non-cancéreux, 
admis consécutivement en consultation après d'une 
équipe de soins palliatifs dans un hôpital universitaire 
suisse, avec les dossiers de 506 patients attteints du 
cancer et· admis également au cours de la même 
période. La fréquence des symptômes dont les 
malades faisaient état étaient la même pour les deux 
groupes. Les principales raisons pour lesquelles le 
premier groupe avait été dirigé en consultation étaient 
le contrôle des symptômes, l'évaluation globale du 
malade et l'assistance pour le congé de l'hôpital. 
Les demandes pour le contrôle de la douleur étaient 
prédominantes dans le deuxième groupe. Avant leur 
première visite, 50 % des patients du premier groupe 
étaient sous opioïdes comparativement à 58 % dans le 
deuxième groupe de patients. Après leur première 
visite la proportion des patients du premier groupe 
sous opioïdes a grimpé à 64 % et celle du deuxième 
groupe à 73 %. La dose moyenne quotidienne de mor-
phine par voie orale pour les patients du premier 
groupe avant la première consultation était plus élevée 
que pour les patients du deuxième groupe (6 mg c. 
45 mg). Au moment du décès ou du congé de l'hôpital 
le pourcentage des patients du premier groupe sous 
opioïdes était de 64 % alors que pour le deuxième 
groupe il était de 76 %. La moitié des patients du 
premier groupe, soit 50 %, sont décédés au cours de 
leur hospitalisation alors que dans le cas du deuxième 
groupe le pourcentage était de 33 %. Seulement 6 % 
des patients du premier groupe ont été traité dans 
l'unité de soins palliatifs comparativement à 20 % dans 
le deuxième groupe. 
INTRODUCTION 
Over the last decades, palliative care in most 
regions of the world has largely focused on the 
needs of terminally i1l cancer patients (1). More 
recently, .the focus has justifiably broadened to 
include non-cancer patients and patients much 
earlier in their illness trajectories (2). To highlight 
thè need to implement a palliative care approach 
earlier in the illness trajectory, the World Health 
Organization (WHO) enlarged its original defini-
tion of palliative care in 2002 to indu.de patients 
with life-threatening illnesses, not just those with 
a progressive incurable illness (3). A growing 
number of studies are reporting that patients with 
progressive incurable non-cai1cer illnesses also 
experience a variety of comparable problems -
including physical, psychosocial, and spiritual 
distress - that have a negative impact on their 
quality of life (4-12). Several authors have stressed 
the ethical imperative of addressing the needs 
of these patients and the necessity for specialist 
palliative care services to include such patients in 
their mandates (4, 13). 
Unfortunately, with some notable exceptions, it 
appears that only a minority of non-cancer 
patients with palliative-care-related peeds receive 
palliative care or are referred to specialist pallia-
tive care (14, 15). The reasons for this are probably 
varied; they may include a lack of understanding 
of these patients' needs and of how specialized 
palliative care units can contribute (16). Moreover, 
illness development and prognosis for these 
patients are generally less predictable than they 
are for oncology patients (17). 
This article reports the results of a retrospèctive 
study that was conducted to better understand 
differences between non-cancer patients and 
cancer patients referred to a palliative care consult 
team in a university hospital in Switzerland -
specifically, in terms of referral patterns, symptom 
profiles, medications used, and recommendations 
made. 
METHODS 
The University Hospital of the Canton of Vaud 
(CHUV) is a 900-bed university hospital that 
serves the city of Lausanne and the Canton of 
Vaud in Switzerland. Since October 1996, the 
CHUV has had an interdisciplinary palliative 
consult team (PCT), which receives referrals from 
units or wards for cancer and non-cancer termi-
nally ill patients (18). 
We reviewed the hospital charts of 100 consec-
uti ve non-cancer patients referred to the PCT 
between April 2000 and November 2001. Infor-
mation was extracted using a predeterrnined data-
extraction form. Information on the 506 cancer 
patients referred to the PCT during the same 
period was also analyzed to allow for comparison 
between the non-cancer and cancer subpopula-
tions. Demographic data were collected, along 
with information on length of hospitalization, 
reasons for referral to the PCT, time period from 
admission to the first referral to the PCT, and time 
period between the PCT's first intervention and 
the patient's discharge or death. 
Sorne patients were unable to communicate for 
such reasons as cognitive impairment or coma. In 
this study, patients were categorized as either 
"able to communicate" or "unable to communi-
cate" based on the PCT's and the attending teams' 
chart notes. Symptoms of patients able to commu-
nicate were evaluated at the PCT's first visit. A 
symptom was identified as present if it exceeded 
2 on a numerical scale (0 to 10), or if it was defined 
as more than "mild pain" on the verbal scale ("no 
pain," "mild pain," "moderate pain," and "severe 
pain"), which is used by the PCT as part of the 
Edmonton Symptom Assessment Scale (19). 
Information on each patient's analgesic and adju-
vant medications was extracted - specifically, the 
types and doses of medications taken just prior to 
the first PCT visit, those recommended by the 
PCT, and those taken on the patient's day of dis-
charge or death. When a medication had the 
potential to treat several problems, it was catego-
rized as an analgesic or adjuvant analgesic only if 
chart notes specified that the purpose for which it 
was prescribed was pain. The daily opioid doses 
were standardized by calculating the equivalent 
oral morphine daily dose (20). Only analgesics 
given regularly (around the dock) were analyzed. 
Changes in the type of opioid (opioids rotation) 
were also recorded. 
Ali the data for non-cancer and cancer patients 
referred to the PCT were compared. Distributions 
were expressed as means with standard deviation, 
medians with interquartile ranges, and nominal 
and ordinal data described as frequencies and per-
centages. Comparisons between cancer and non-
cancer patients were done using the non-paramet-
ric Wilcoxon rank-sum test or the Wilcoxon 
signed-rank test to assess changes in opioid doses 
within a groùp. Ability to communicate, referring 
wards, places to which the patients were dis-
charged, and sex prevalence were compared using 
the chi-square (X2) test. Statistical significance was 
set at p<0.05. Statistical analysis was carried out 
using the analytical software Statistix 7. 
The study protocol was reviewed and ap-
proved by the research ethics committee of the 
University of Lausanne' s Faculty of Biology and 
Medicine. 
RESULTS 
Patient demographic information and hospital-
stay information is listed in Table 1. Non-cancer 
patients were significantly older than cancer 
patients, and there was a predominance of women 
in the former group. The main diagnoses in the 
non-cancer group were cardiovascular (stroke in 
18 patients, 12 cases of cardiac failure, and 12 
cases of arterial occlusive disease) and neurologi-
cal diseases (notably, head injuries in 6 patients, 5 
cases of multiple sclerosis or a~yotrophic fateral 
sclerosis, and 4 cases of dementia). Collectively, 
these conditions accounted for 62 percent of all 
the diagnoses in this group. In the infectious 
disease subgroup, 4 patients had acquired im-
mune deficiency syndrome (AIDS), and 2 patients 
in the gastrointestinal subgroup presented with 
end-stage cirrhosis of the liver. The 5 patients with 
pulmonary disease had chronic obstructive pul-
monary disease (COPD). In the cancer group, 
primary cancer types were gastrointestinal in 141 
patients (28 percent), lung in 101 (20 percent), gen-
itourinary in 81 (16 percent), head and neck in 56 
93 
94 
(11 percent), hematological in 35 (7 percent), breast 
in 31 (6 percent), and other in 61 (12 percent). The 
median length of hospital stay was longer for non-
car\cer patients than for cancer patients (24 versus 
20 days; p=0.015). A significantly higher propor-
tion of non-cancer patients died during hospital-
ization than cancer patients (56 percent versus 33 
percent; p :S:0.01). Discharge locations differed sig-
nificantly between the two groups. Non-cancer 
patients were more often transferred to long-term-
care facilities (nursing homes for the elderly); 
cancer patients more often returned to their 
homes or were transferred to palliative care units. 
The referral patterns to the PCT are listed in 
Table 2. The distribution of the referring units was 
similar for the non-cancer and the cancer patients. · 
In both cases, the main referring ward was the 
general internal medicine unit, which is the 
CHUV unît that usually cares for patients with 
advanced cancer. The oncology unit focuses on 
patients with potentially curable illnesses who are 
undergoing aggressive chemotherapy and require 
specialized monitoring. The reasons for referring 
differed significantly between the two groups. 
Requests for specific symptom control were lower 
for the non-cancer group than for the cancer 
group. Requests for a global evaluation (meaning 
that the attending physician did not specify a 
reason) and for assistance in discharge planning 
were significantly higher for the non-cancer group 
than for the cancer group. The median delay from 
admission to first referral to the PCT was more 
than twice as long for non-cancer patients (12 
days for cancer patients versus 5 days for non-
cancer patients; p<0.01). Conversely, the median 
number of days from the first PCT visit to dis-
charge or death was shorter for the non-cancer 
patients (11 days versus 8 days; p=0.03). 
At the first visit from the PCT, only 42 non-
cancer patients (42 percent) were able to commu-
nicate adequately compared to 405 in the cancer 
group (80 percent) (p<0.01). Inability to communi-
cate was caused by a variety of factors, including 
aphasia, cognitive dysfonction, and altered level 
of consciousness. 
The symptoms and problems identified in 
patients who could communicate adequately are 
listed in Table 3. In these patients, in both groups, 
Table 1 / Demographic Information and Diagnoses of Patients Referredto the PCT 
Non-cancer Cancer 
patients patients 
(N = 100) (N = 506) p-value 
Age (years) <0.01 
Mean± SD 75±16 66 ± 13 
Median (range) 81 (25-99) 67 (20-94) 
Gender, women 68 (68%) 219 (43%) <0.01 
Diagnosis of non-cancer patients 
Cardiovascular disease 42 (42%) 
Neurological disease 20 (20%) 
lnfectious disease · 14 (14%) 
Gastrointestinal disease 9(9%) 
Pulmonary disease 5(5%) 
Kidney disease 4(4%) 
Others 6(6%) 
Primary sites of cancer of cancer patients 
Gastrointestinal 141 (28%) 
Lung 101 (20%) 
Genitourinary 81 (16%) 
Head and neck 56 (11%) 
Haematological 35(7%) 
Breast 31 (6%) 
Other 61 (12%) 
Length of stay in hospital (days), median (range) 24 (1-423) 20 (1-237) 0.015 
Number of patients who died during hospitalization 56 (56%) 169 (33%) <0.01 
Discharge sites for patients discharged from hospital 44 337 <0.01 
Palliative care unit• 6(14%) 109 (32%) 
Home 10 (25%) 147 (43%) 
Other hospital 20 (45%) 70 (20%) 
Long-term care facility 8 (18%) 11 (3%) 
'Four hospice units for more "stable" patients in the canton (a free standing hospice unit and three others attached to small community 
rehabilitation centres). 
Table 2 I Referral Patterns to the PCT 
Non-cancer Cancer 
patients patients 
(N = 100) (N= 506) p-value 
Referring service 0.16 
Emergency 2 (2%) 13(3%) 
General Internai Medicine 51 (51%) 265 (52%) 
Others specialtiesa 18 (18%) 60 (12%) 
General Surgery 9 (9%) 85 (17%) 
Surgical subspecialtiesb 20 (20%) 83 (16%) 
Reasons for the initial referra/c <0.01 
Symptom contrai 40 (40%) 311 (61%) 
Pain 30 (30%) 249 (49%) 
Dyspnea 4(4%) 22 (4%) 
Gastrointestinal symptoms - 33 (7%) 
Other 6(6%) 7 (1%) 
Global evaluation 36 (36%) 105 (21 %) 
Assistance with discharge 22 (22%) 63 (11%) 
Other reasons 2 (2%) 27(5%) 
Length of time from admission until the first PCT visit 
{days), median (range) 12 (0-351) 5 (0-217) <0.01 
Length of time from the first PCT visit to discharge (days), 
median (range) 8 (0-145) 11 (10-183) 0.03 
Length of time from the first PCT visit until death 
for patients who died in hospital (days), median (range) 5 (0-125) 8 (0-67) 0.05 
• Neurology, oncology, radiation oncology, rheumatology, dermatology, cardiology 
b Neurosurgery, gynaecology, orthopaedic, cardiovascular surgery, urology, ear-nose-throat (ENT) 
0 These reflect what the referring team indicated on their referral notes. Note that a higher proP,ortion of non-cancer patients than cancer patients 
were unable to communicate and the reasons for referral may therefore not accurately reflect the real needs of patients. 
Table 3 I Prevalence of Symptoms in Patients Able to Communicate 
Symptoms 
Fatigue 
Pàin 
Anxiety, depression 
No appetite 
Dyspnoea 
Constipation. or diarrhoea 
Sleep problems 
Nausea or vomiting 
Mouth dryness 
Other symptoms 
the prevalence of physical and psychological 
symptoms was high. Pain and fatigue were 
both identified in approximately two-thirds of 
non-cancer and cancer patients. Depressed and 
anxious moods were also common in the two 
groups. A majority of both non-cancer and cancer 
patients were experiencing three or more symp-
toms (79 percent and 71 percent, respectively). 
Table 4 summarizes opiciid use in the two 
groups prior to the intervention of the PCT, after 
the first visit by the PCT, and at the time of death 
or discharge. Prior to the first PCT visit, 50 non-
cancer patients (50 percent) were on opioids 
(weak and strong) compared to 294 cancer 
patients (58 percent) (p=0.05). After the first visit, 
the number of non-cancer patients on (weak and 
Non-cancer Cancer 
patients patients 
(N=42) (N= 404) p-value 
32 (76%) 279 (69%) 0.34 
28 (67%) 268 (66%) 0.96 
24 (57%) 174 (43%) 0.08 
23 (55%) 218 (54%) 0.92 
15 (36%) 95 (24%) 0.08 
13(31%) 100 (25%) 0.38 
7 (17%) 43 (11%) 0.24 
6(14%) 74 (18%) 0.52 
3(7%) 45 (11%) 0.43 
9 (21%) 59 (15%) 0.24 
strong) opioids increased to 64 (64 percent). This 
did not represent a significant increase (p=0.14). 
The number of cancer patients on (weak and 
strong) opioids also increased to 367 (73 percent). 
This was statistically significant (p<0.001). 
The median daily oral morphine equivalent 
dose for non-cancer patients taking opioids 
prior to the first PCT visit was higher than that 
for cancer patients (6q mg versus 45 mg), but 
this difference was not statistically significant 
(p=0,28). At the time of death or discharge, the 
percentage of non-cancer patients on opioids was 
lower than that of cancer patients (64 percent 
versus 76 percent; p=0.01). Moreover, non-cancer 
patients were on significantly lower median 
doses of opioids than cancer patients (31 mg 
95 
96 
Table 4 I Opioid Use in Non-Cancer Versus Cancer Patients 
Opioids prior to PCT visit 
Number of patients on opioids* (%) 
Median daily dose equivalent of oral morphine 
in mg (range) 
Opioids fol/owing first visit by the PCT 
Number of patients on opioids*(%) 
Median daily dose equivalent of oral morphine 
in mg (range) 
Opioids the day of the discharge or death 
Number of patients on opioids* (%) 
Median daily dose equivalent of oral morphine 
in mg (range) 
' Between cancer and non-cancer population 
• Weak and strong opioids combined 
versus 60 mg; p :o:;0.01). Table 5 explores in more 
depth the use of analgesics and adjuvant anal-
gesics in the non~cancer and cancer groups. 
Similar percentages of non-cancer and cancer 
patients were on analgesics prior to the first visit: 
71 (71 percent) versus 379 (75 percent), respec-
tively (p=0.42). Many patients were on more than 
one analgesic at the same time; 17 of the 71 non-
cancer patients were. on two different analgesics 
(24 percent), and 4 patients (6 percent) were 
taking three different analgesics simultaneously. 
Of the cancer patients, 141 of the 379 on anal.-
gesics (37 percent) were initially on two different 
analgesics, and 42 (11 percent) were on three dif-
ferent ones. 
Non-cancer Cancer 
patients patients 
(N = 100) (N= 506) p-value• 
0.16 
50 (50%) 294 (58%) 0.05 
60 mg (10-360) 45 mg (5-540) 0.28 
<0.01 
64 (64%) 367 (73%) 0.09 
30 mg (10-240) 45mg (5-864) 0.05 
64 (64%) 386 (76%) 0.01 
31 mg (8-240) · 60mg (5-1320) <0.01 
Pri6r to the first PCT visit, 9 of the 71 non-
cancer patients on analgesics (13 percent) were 
taking non-steroidal anti-inflammatory drugs, 
compared to 93 (25 percent) in the cancer group; 9 
non-cancer patients (13 percent) were on weak 
opioids versus 72 cancer patients (19 percent) 
(p=0.16), and 41 non-cancer patients (58 percent) 
were on strong ôpioids versus 222 cancer patients 
(59 percent) (p=0.55). These differences were not 
statistically significant. However, significantly 
more cancer patients were on adjuvant analgesics 
than non-cancer patients: 131 (26 percent) versus 
8 (8 percent) (p<0.01). Surprisingly, none of the 
non-cancer patients were on tricyclic antidepres-
sants as adjuvant analgesics prior to the first PCT 
Table 5 I Analgesics and Adjuvant Medications Taken by Non-Cancer and Cancer Patients 
Non-cancer patients Cancer patients 
Prior to Following Prior to Following 
first visit first visit first visit first visit 
of PCT of PCT of PCT of PCT 
(N = 100) (N = 100) p-value (N= 506) (N= 506) p-value 
Analgesics 
(total number of patients 
on one or more analgesics) 71 (71%) 85 (85%) 0.058 379 (75%) 422 (83%) . 0.0039 
Acetaminophen 37 (52%) 52 (61%) 220 (58%) 202 (48%) 
Non-steroidal 
anti-inflammatory agents 9 (13%) 13 (15%) 93 (25%) 86 (20%) 
Weak opioids 9 (13%) 5(6%) a 72 (19%) 50 (12%) a 
Strong opioids 41 (58%) 59 (69%) 0.039 222 (59%) 317 (75%) <0.001 
Adjuvant analgesics• 8(8%) 20 (20%) 131 (26%) 183 (36%) 
Gabapentin 1 (13%) 14 (70%) 24 (18%) 53 (29%) 
Ôther anticonvulsants 1 (13%) 0(0%) 1 (1%) 9(5%) 
Tricyclic antidepressants - - 7(5%) 5(3%) 
Corticosteroids - - 91 (69%). 135 (74%) 
Hyoscine butylbromide 1 (13%) 1(5%) 10(8%) 11 (6%) 
Baclofen 4(50%) 3 (15%) 7(5%) -
Biphosphonates 1 (13%) 2 (10%) 7 (5%) 21 (12%) 
Epidural bloc/< 1 (13%) 1 (5%) a 1 (1%) 1 (0.5%) a 
'Small numbers exclude inferential statistics. 
visit. Gabapentin and other anticonvulsant med-
ica tions were being used in almost identical 
amounts in bath groups. 
After the first visit by the PCT te(lm, there was 
an increase in the number of patients on strong 
opioids and on adjuvant analgesics in the non-
cancer group. Much of the increase in adjuvant 
analgesics was attributable to increased use qf 
gabapentin (from 13 percent of patients priôr to 
the first PCT visit to 70 percent after the visit). The 
proportion of patients on weak opioids decreased 
(from 13 to 6 percent). In the cancer group, there 
was also an increase in the number and propor-
tion of patients on strong opioids initially versus 
after the first visit (59 to 75 percent), accompanied 
by a reduction in the number and proportion of 
patients on weak opioids (19 to 12 percent). The 
use of gabapentin was also increased in the cancer 
group. 
Following the first visit, the PCT recommended 
that opioids be introduced for 18 non-cancer 
patients (18 percent) and 81 cancer patients (16 
percent) (p==0.62) who had not previously been on 
opioids. With patients already taking opioids, the 
PCT recommended dose increases for 12 of the 50 
non-cancer patients already on opioids (24 
percent) and 138 of the 294 cancer patients (47 
percent), whereas a dose decrease was recom-
mended in 18 (36 percent) and 47 (16 percent) 
non-cancer and cancer patients, respectively 
(p==0.01). In the non-cancer group, the main reason 
for a decrease appeared to be clinical signs of 
opioid overdosing. In all these patients, the signs 
abated after the dose was decreased. In cancer 
patients, opioid doses were decreased either in the 
context of reducing doses to manage opioid neu-
rotoxicity or in the context of switching opioids 
and reducing the doses of the new opioids (in 
accordance with clinical guidelines, equianalgesic 
doses of the new opioids are routinely reduced by 
another 20 to 50 percent). The PCT ordered that 
opi~ids be withheld altogether for one non-cancer 
patient and five cancer patients. Changes in the 
type of opioid were recommended equally in the 
non-cancer and the cancer groups already on 
opioids (26 percent of non-cancer patients versus 
27 percent of cancer patients). 
DISCUSSION 
This study found several significant similarities 
and differences between the clinical profiles and 
referral patterns of terminally ill non-cancer 
patients and terminally ill cancer patients referred 
to a PCT in a Swiss university hospital. 
Pain and fatigue were documented in more than 
two-thirds of bath non-cancer and cancer patients. 
Psychological symptoms were also highly preva-
lent in bath groups, with approximately half of 
the patients reporting depressed and anxious 
moods. These findings are consistent with those of 
other studies that investigated the prevalence of 
- symptoms in non-cancer terminally ill patients (5, 
21, 22). These studies have reported prevalence 
rates of pain varying from 49 to 77 percent, and of 
fatigue varying from 38 to 84 percent. Depression 
also appears common, occurring in about 50 
percent of patients. Solana, Gomes, and Higgin-
son, in a review of 64 studies involving end-stage 
patients suffering from cancer, AIDS, COPD, and 
heart and renal diseases, reported that some 
symptoms - such as pain, depression, fatigue, 
anorexia, and dyspnea - are often as prevalent in 
advanced non-cancer as in advanced cancer (23). 
They hypothesized a common pathway toward 
death for malignant and non-malignant diseases. 
In our study population, 79 percent of non-cancer 
patients and 71 percent of cancer patients were 
experiencing three symptoms or more. Tranmer 
et al., using a systematic evaluation with the 
Memorial Symptom Assessment Scale in a pro-
spective study involving cancer and non-cancer 
patients, reported an average of 10 symptoms per 
patient in both groups (22). 
In this study, non-cancer patients were referred 
to the PCT later tha~1 cancer patients. Conse-
quently, the median time between PCT referral 
and discharge or death was very short: only five 
days for non-cancer patients who <lied in hospital. 
Follow-up was therefore often impossible. The 
need to improve the quality of life of patients with 
progressive incurable diseases by initiating pal-
liative care earlier in the course of their illness is 
recognized internationally. The most recent defini-
tion provided by the WHO stresses this point (3). 
Late referral to palliative care services appears to 
be a problem common to non-cancer and cancer 
patients (24-26). The barriers to early referral have 
previously been identified (27, 28). These include: 
the unwillingness of patients and their families to 
receive palliative care, and their misconceptions 
about palliative care; the unwillingness of physi-
cians to discuss end-of-life care with patients and 
their fa~ilies; a lack of information and training 
on palliative care intervention arriong health and 
social care professionals; and a lack of awareness 
about the availability of palliative care units. 
However, this study suggests that late referral 
may be more common for non-cancer patients 
than for cancer patients. 
Additional factors may account for this. In 
non-cancer patients, illness trajectories a'nd life 
expectancy are generally more unpredictable than 
they are in cancer patients (29). This may be a sig-
nificant barrier to switching, in a timelier manner, 
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to a palliative car~ approach or referring to pallia-
tive care services. Various prognostic tools have 
been developed to assist in estimating survival in 
this population, but they have proven inaccurate 
(30). For Field and Addington-Hall, this difficulty 
in evaluating a prognosis is "the key blockage" to 
extending palliative care to these patients (4). 
Moreover, the role of palliative care services may 
not be fully appreciated or well understood by 
attending health teams. A focus on specific symp-
toms related to the diagnosis rather than a recog-
nition of the whole picture, as well as difficulties 
in identifying non-cancer patients as candidates 
for palliative care, are additional barriers (16). 
The factors that explain the delay in referral 
may also explain the patterns of referral to the 
PCT. The higher number of requests for global 
evaluations of non-cancer patients may reflect 
uncertainty as to the needs of these patients and 
the difficulty of evaluating these needs, particu-
larly in the case of non-communicating patients. 
The higher rate of requests for assistance in dis-
charge planning may reflect not only these diffi-
culties, but also the problem of identifying the 
optimal place of care and the limited availability 
of resources in the community for these patients. 
The percentage of patients on analgesics was 
similar in the two groups prior to the first PCT 
visit. Among these, a slightly smaller percentage 
of non-cancer patients was receiving weak or 
strong opioids. An increase in the number of 
patients on opioids following the PCT interven-
tion was seen in both groups. However, interest-
ingly, the median opioid dose being used 
decreased in the non-cancer group and increased 
in the cancer group. In several non-cancer cases, 
this was due to clinical signs of relative opioid 
overdosing. While opioids have been shown to be 
safe and useful in managing pain and dyspnea in 
this population (31, 32), the recommendations for 
dose decreases recorded in this study may reflect 
a lack of experience or accuracy in evaluating pain 
and the appropriate use of opioids. There may be 
an overreliance on opioids as a standard treatment 
toward the end of life, whether or not patients 
actually have pain. The advanced age of our non-
cancer patients (a median of 81 years; 67 years 
among cancer patients) may have also played a 
role. Controlled studies have demonstrated that 
older patients are more sensitive to the effects of 
opioids (33-35), and they are more susceptible to 
adverse effects because of the age-related physio-
logical changes that affect the pharmacokinetics 
and pharmacodynamies of the drugs (36, 37). 
The major limitation of this study is its retro-
spective design. While all efforts were made to 
retrieve data accurately, the results may not 
exactly reflect the needs of patients. The inability 
of many patients to communicate and the lack of 
a systematic use of clinical instruments to evalu-
ate needs and cognition posed challenges. In addi-
tion, the level of compliance of the attending 
teams to the recommendations provided by the 
PCT could not be evaluated. The study may not 
truly reflect the situation of all patients with pal-
liative-care-related needs in our hospital, as not all 
patients with incurable progressive illnesses are 
referred to the PCT. 
CONCLUSION 
Despite its limitations, this study demonstrates 
both relevant similarities and noticeable differ-
ences between non-cancer patients and cancer 
patients referred to a PCT in a Swiss university 
hospital. The finding that non-cancer patients are 
being referred to palliative care services very la te 
in the course of their illness warrants further 
exploration. We must determine why this is hap-
pening and develop strategies to eliminate the 
barriers to providing these patients with earlier 
care. Estahlishing institutional guidelines to better 
identify patients who require palliative care and to 
refer them in a timely manner to palliative care 
specialist services may be of these strategies. 
Barriers - including lack of resources - to 
discharging non-cancer patients whose goals of 
care are palliative also need to be addressed. 
Recommendations by the PCT to increase opioid 
use in both cancer and non-cancer patients speak 
to the usefulness of these treatments for pain 
control. However, the need to recommend de-
creases in opioid doses in several non-cancer and 
cancer patients should be explored further, as it 
may indicate a lack of expertise in, and under-
standing of, the role of opioids in this patient pop-
ulation on the part of non-palliative specialists. 
Clearly, further research is warranted to clarify the 
needs of non-cancer patients and identify and 
evaluate strategies to address them. 
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